The ORR was 25% and the clinical benefit rate was 93%; of note, the ORR for patients with pathogenic variants of the SDHB gene was 60%.36 Almost all patients with SD had some degree of tumor regression; most of these patients had large tumors that, although substantially decreased in size, did not reach PR status (e.g., a patient with target lesions that measured 10 cm at baseline and decreased by 2 cm after cabozantinib was considered to have SD per RECIST 1.1). Here, SDHB is linked to neoplasm.